Holen Sie sich die Stockscreener-App
62.57
2.82%
-1.7167
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics, Inc. (PTCT) - DirectorsTalk Interviews
Oversold Conditions For PTC Therapeutics (PTCT) - Nasdaq
PTC Therapeutics (PTCT) Gains Edge as Competitor Faces Setback - GuruFocus
PTC Therapeutics Grants Stock Options and RSUs to New Employees - Intellectia AI
Assessing PTC Therapeutics (PTCT) Valuation After Contrasting Quarterly Loss And Full Year Profit Turnaround - Sahm
JPMorgan Chase & Co. Reduces Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics vs Merck: Which Is the Stronger Buy Today? - Trefis
GSA Capital Partners LLP Decreases Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTCT Should I Buy - Intellectia AI
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
16,062 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Private Capital Advisors Inc. - MarketBeat
PTC Therapeutics, Inc. $PTCT Holdings Decreased by Vanguard Group Inc. - MarketBeat
PTC Therapeutics Experiences Revision in Stock Evaluation Amid Mixed Financial Performance - Markets Mojo
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2025 earnings call transcript - MSN
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2025 Earnings Call Transcript - Insider Monkey
PTC Therapeutics outlines 19%-36% 2026 product revenue growth target as Sephience momentum accelerates globally - MSN
How Translarna NDA Withdrawal and Mixed Results Will Impact PTC Therapeutics (PTCT) Investors - Sahm
PTC Therapeutics, Inc. (PTCT) Stock Analysis: Exploring a 24.21% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells 3,019 Shares of Stock - MarketBeat
PTC Therapeutics (PTCT) CLO Boulding sells 3,019 shares under 10b5-1 plan - Stock Titan
PTC Therapeutics to Participate at Upcoming Investor Conferences - GuruFocus
Morgan Stanley raises PTC Therapeutics stock price target on OpEx cuts - Investing.com Australia
PTC Therapeutics: Sephience As A Major Growth Driver (NASDAQ:PTCT) - Seeking Alpha
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
How Sephience Is Reshaping The Story For PTC Therapeutics (PTCT) And Analyst Expectations - Yahoo Finance
PTC Therapeutics, Inc. $PTCT Shares Sold by Hillsdale Investment Management Inc. - MarketBeat
19,142 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Brummer Multi Strategy AB - MarketBeat
PTC Therapeutics (PTCT) Q4 earnings: Taking a look at key metrics versus estimates - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Guardant Health (GH) and PTC Therapeutics (PTCT) - The Globe and Mail
PTC Therapeutics (NASDAQ:PTCT) Cut to "Hold" at Wall Street Zen - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CAO Sells 2,494 Shares of Stock - MarketBeat
Lee Scott Golden Sells 2,484 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 3,019 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 3,056 Shares - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CFO Pierre Gravier Sells 2,992 Shares - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells 7,371 Shares of Stock - MarketBeat
PTC’s Sephience Launch Appears Off To A Strong Start - Citeline News & Insights
Cantor Fitzgerald reiterates Overweight on PTC Therapeutics stock By Investing.com - Investing.com Canada
PTC Therapeutics (NASDAQ:PTCT) Trading Down 6.5% on Disappointing Earnings - MarketBeat
PTC Therapeutics (PTCT): RBC Capital Lowers Price Target to $82 - GuruFocus
Bank of America Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $93.00 - MarketBeat
B of A Securities Lowers Price Target for PTC Therapeutics (PTCT) to $93 | PTCT Stock News - GuruFocus
PTC Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
PTC Therapeutics Inc (PTCT) Q4 2025 Earnings Call Highlights: Su - GuruFocus
Cantor Fitzgerald Keeps Overweight on PTC Therapeutics (PTCT) Feb 20 2026 - Meyka
PTC Therapeutics exec. VP Boulding sells $408,612 in stock By Investing.com - Investing.com Canada
PTC Therapeutics exec. VP Boulding sells $408,612 in stock - Investing.com Australia
Decoding PTC Therapeutics Inc (PTCT): A Strategic SWOT Insight - GuruFocus
PTC Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
PTC Therapeutics Q4 Earnings Call Highlights - MarketBeat
PTC Therapeutics earnings missed by $1.41, revenue fell short of estimates - Investing.com Canada
PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates - sharewise.com
PTC Therapeutics (PTCT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
PTC Therapeutics Q4 2025 Financial Results: Loss, Revenue ShortfallNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
PTC Therapeutics: Q4 Earnings Snapshot - KVUE
Mark Elliott Boulding Sells 3,081 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics: Fourth Quarter Financial Highlights - Bitget
PTC Therapeutics stock down over 2% on worse-than-expected Q4 results, guidance - Yahoo Finance
PTCT Revenue Forecast Nears $1 Billion by 2026 - GuruFocus
Earnings Flash (PTCT) PTC Therapeutics Posts Q4 Loss $1.67 per Share - marketscreener.com
PTC Therapeutics (NASDAQ:PTCT) Issues Quarterly Earnings Results - MarketBeat
PTC Therapeutics Tops 2025 Revenue Guidance, Boosts Cash - TipRanks
Earnings Flash (PTCT) PTC Therapeutics, Inc. Reports Q4 Revenue $164.7M, vs. FactSet Est of $279.5M - marketscreener.com
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Yahoo Finance
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):